Mark L Heaney

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs
    Mark L Heaney
    Departments of Medicine and Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Res 68:8031-8. 2008
  2. ncbi The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies
    Luca Paoluzzi
    Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
    Blood 112:2906-16. 2008
  3. ncbi Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses
    Nicole Lamanna
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 27:491-7. 2009
  4. ncbi Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
    Owen A O'Connor
    Department of Medicine, Division of Hematologic Oncology, Lymphoma Service, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, NY 10021, USA
    J Clin Oncol 24:166-73. 2006
  5. ncbi Inhibition of human peptide deformylase disrupts mitochondrial function
    Sindy Escobar-Alvarez
    Molecular Pharmacology and Chemistry, Sloan Kettering Institute, New York, NY 10065, USA
    Mol Cell Biol 30:5099-109. 2010
  6. ncbi Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia
    Todd L Rosenblat
    Department of Medicine and the Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:5303-11. 2010
  7. ncbi Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis
    Priya Koppikar
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 115:2919-27. 2010
  8. ncbi A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia
    Prabodhika R Mallikaratchy
    Sloan Kettering Institute, 1275 York Ave, New York, New York 10025, USA
    Nucleic Acids Res 39:2458-69. 2011
  9. ncbi Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia
    Mark L Heaney
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 115:4839-48. 2009
  10. ncbi Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
    Luca Paoluzzi
    Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
    Blood 111:5350-8. 2008

Collaborators

Detail Information

Publications11

  1. ncbi Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs
    Mark L Heaney
    Departments of Medicine and Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Res 68:8031-8. 2008
    ..These results support the hypothesis that vitamin C supplementation during cancer treatment may detrimentally affect therapeutic response...
  2. ncbi The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies
    Luca Paoluzzi
    Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
    Blood 112:2906-16. 2008
    ..Collectively, these data suggest that ABT-737 alone or in combination with a proteasome inhibitor represents a novel and potentially important platform for the treatment of B-cell malignancies...
  3. ncbi Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses
    Nicole Lamanna
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 27:491-7. 2009
    ..In that study, cyclophosphamide consolidation improved the frequency of complete response (CR) four-fold. Subsequently, rituximab was added to this regimen (F-->C-->R)...
  4. ncbi Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
    Owen A O'Connor
    Department of Medicine, Division of Hematologic Oncology, Lymphoma Service, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, NY 10021, USA
    J Clin Oncol 24:166-73. 2006
    ..To document the toxicity and activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with pretreated hematologic malignancies...
  5. ncbi Inhibition of human peptide deformylase disrupts mitochondrial function
    Sindy Escobar-Alvarez
    Molecular Pharmacology and Chemistry, Sloan Kettering Institute, New York, NY 10065, USA
    Mol Cell Biol 30:5099-109. 2010
    ..Therefore, HsPDF appears to have a role in maintenance of mitochondrial respiratory function, and this function is analogous to that of chloroplast PDF...
  6. ncbi Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia
    Todd L Rosenblat
    Department of Medicine and the Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:5303-11. 2010
    ..This phase I/II trial was conducted to determine the maximum tolerated dose (MTD) and antileukemic effects of (213)Bi-lintuzumab, the first targeted α-emitter, after partially cytoreductive chemotherapy...
  7. ncbi Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis
    Priya Koppikar
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 115:2919-27. 2010
    ..However, we did not observe a decrease in the size of the malignant clone in the bone marrow of treated mice at the end of therapy, which suggests that JAK2 inhibitor therapy, by itself, was not curative in this MPN model...
  8. ncbi A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia
    Prabodhika R Mallikaratchy
    Sloan Kettering Institute, 1275 York Ave, New York, New York 10025, USA
    Nucleic Acids Res 39:2458-69. 2011
    ..The chemically engineered aptamers, with significantly improved kinetic and biochemical features, unique specificity and desirable pharmacological properties, may be useful in biomedical applications...
  9. ncbi Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia
    Mark L Heaney
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 115:4839-48. 2009
    ..Therefore, GM-CSF might reduce infection risk more than the G-CSFs. This study compared real-world infection-related hospitalization rates and costs in patients using G/GM-CSF for chemotherapy-induced neutropenia...
  10. ncbi Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
    Luca Paoluzzi
    Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
    Blood 111:5350-8. 2008
    ..The addition of AT-101 to cyclophosphamide (Cy) and rituximab (R) in a schedule-dependent manner enhanced the efficacy of the conventional therapy...
  11. ncbi Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics
    Mona D Lee
    Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Invest 114:1107-16. 2004
    ..We conclude that HsPDF is a new human mitochondrial enzyme that may provide a novel selective target for anticancer therapy by use of actinonin-based antibiotics...